Literature DB >> 32046454

Upregulation of HLA-Class I and II in Placentas Diagnosed with Villitis of Unknown Etiology.

Elizabeth Ann L Enninga1, Alexey A Leontovich2, Bohdana Fedyshyn3, Laurie Wakefield4, Manish Gandhi4, Svetomir N Markovic5, Rodrigo Ruano3, Sarah E Kerr6.   

Abstract

The placenta utilizes many mechanisms to protect the haploidentical fetus from recognition by the maternal immune system. However, in cases of villitis of unknown etiology (VUE), maternal lymphocytes gain access into the placenta, causing significant health risks for the fetus. Evidence suggests that VUE is a rejection response between the mother and the haploidentical fetus. Therefore, we profiled human leukocyte antigen (HLA), an important predictor of transplant rejection, in VUE using placental tissue from ten patients with VUE and ten gestational age matched controls. Placentas were stained using novel multiplexed immunofluorescence (MxIF) to investigate morphology and HLA classes I and II. Gene expression was evaluated by microarray, and where available, tissue typing of mother/baby pairs was completed to determine HLA type. MxIF demonstrated strong CD8+ T cell infiltration and HLA class I staining both the distal and stem villi of VUE placentas. Compared to controls, VUE cases had significantly higher expression of HLA class II mRNA and pathway analysis demonstrated that 40% of the differentially expressed genes in VUE are related to tissue rejection. The data suggest that VUE resembles a rejection response between the mother and the fetus. It remains unknown what initiates immune recognition and why some mothers appear to be at higher risk for developing this condition than others. Understanding this etiology will be critical for developing effective interventions or prevention strategies during pregnancy.

Entities:  

Keywords:  HLA; Inflammation; Placenta; Rejection; Villitis

Mesh:

Substances:

Year:  2020        PMID: 32046454      PMCID: PMC7255550          DOI: 10.1007/s43032-019-00101-9

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  38 in total

Review 1.  Systematic review of placental pathology reported in association with stillbirth.

Authors:  I Ptacek; N J Sebire; J A Man; P Brownbill; A E P Heazell
Journal:  Placenta       Date:  2014-06-06       Impact factor: 3.481

2.  Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop Group Consensus Statement.

Authors:  T Yee Khong; Eoghan E Mooney; Ilana Ariel; Nathalie C M Balmus; Theonia K Boyd; Marie-Anne Brundler; Hayley Derricott; Margaret J Evans; Ona M Faye-Petersen; John E Gillan; Alex E P Heazell; Debra S Heller; Suzanne M Jacques; Sarah Keating; Peter Kelehan; Ann Maes; Eileen M McKay; Terry K Morgan; Peter G J Nikkels; W Tony Parks; Raymond W Redline; Irene Scheimberg; Mirthe H Schoots; Neil J Sebire; Albert Timmer; Gitta Turowski; J Patrick van der Voorn; Ineke van Lijnschoten; Sanne J Gordijn
Journal:  Arch Pathol Lab Med       Date:  2016-05-25       Impact factor: 5.534

3.  Villitis of unknown etiology is associated with major infiltration of fetal tissue by maternal inflammatory cells.

Authors:  R W Redline; P Patterson
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

4.  Villitis of unknown aetiology: its incidence and significance in placentae from a British population.

Authors:  W F Knox; H Fox
Journal:  Placenta       Date:  1984 Sep-Oct       Impact factor: 3.481

5.  Chronic villitis of unknown aetiology in recurrent intrauterine fetal growth retardation.

Authors:  C Labarrere; O Althabe
Journal:  Placenta       Date:  1987 Mar-Apr       Impact factor: 3.481

Review 6.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

7.  Placental pathologic findings in preterm birth.

Authors:  C M Salafia; C A Vogel; A M Vintzileos; K F Bantham; J Pezzullo; L Silberman
Journal:  Am J Obstet Gynecol       Date:  1991-10       Impact factor: 8.661

8.  Enterovirus associated placental morphology: a light, virological, electron microscopic and immunohistologic study.

Authors:  A G Garcia; N G Basso; M E Fonseca; J A Zuardi; H N Outanni
Journal:  Placenta       Date:  1991 Sep-Oct       Impact factor: 3.481

9.  Positive C4d immunostaining of placental villous syncytiotrophoblasts supports host-versus-graft rejection in villitis of unknown etiology.

Authors:  Erin Rudzinski; Meghan Gilroy; Colin Newbill; Terry Morgan
Journal:  Pediatr Dev Pathol       Date:  2012-11-08

Review 10.  Hofbauer Cells: Their Role in Healthy and Complicated Pregnancy.

Authors:  Leticia Reyes; Thaddeus G Golos
Journal:  Front Immunol       Date:  2018-11-15       Impact factor: 7.561

View more
  4 in total

1.  Maternal T Cells in the Human Placental Villi Support an Allograft Response during Noninfectious Villitis.

Authors:  Elizabeth Ann L Enninga; Patrick Raber; Reade A Quinton; Rodrigo Ruano; Nadia Ikumi; Clive M Gray; Erica L Johnson; Rana Chakraborty; Sarah E Kerr
Journal:  J Immunol       Date:  2020-04-22       Impact factor: 5.422

Review 2.  Four major patterns of placental injury: a stepwise guide for understanding and implementing the 2016 Amsterdam consensus.

Authors:  Raymond W Redline; Sanjita Ravishankar; Christina M Bagby; Shahrazad T Saab; Shabnam Zarei
Journal:  Mod Pathol       Date:  2021-02-08       Impact factor: 8.209

Review 3.  Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome.

Authors:  Emily F Cornish; Thomas McDonnell; David J Williams
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

4.  Expression of Immune Checkpoint Receptors in Placentae With Infectious and Non-Infectious Chronic Villitis.

Authors:  Maryam Shahi; Ricardo Mamber Czeresnia; E Heidi Cheek; Reade A Quinton; Rana Chakraborty; Elizabeth Ann L Enninga
Journal:  Front Immunol       Date:  2021-07-30       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.